Life-Sciences Joint-Venture Valuation Board Adviser

The mandate

The proposed joint venture combines assay IP, biomarker data, specialist scientists, laboratory capacity and staged cash contributions, while each party retains different commercial and territorial rights. Negotiators have compressed these elements into one opening ownership percentage. The board wants to understand how value migrates as milestones succeed or fail before it approves capital and governance terms.

The adviser will allocate three days per month to ten decision cycles covering contribution evidence, development scenarios and governance economics. Four board sessions and four partner, laboratory or commercial reviews form the scheduled programme. Questions requiring legal, tax or scientific conclusions are returned to accountable specialists; the adviser tests how their answers affect value and optionality.

The ten-month appointment closes when directors decide formation terms or abandon the transaction. Any renewal for post-formation monitoring requires a new charter, independence review and board vote; no continuing valuation assurance is built into the retainer. If negotiations terminate early, remaining cycles examine exit exposures and reusable diligence evidence rather than extending elsewhere.

There is no line authority and no executive responsibility for negotiation, valuation sign-off, scientific development, tax, IP, accounting or capital approval. Management negotiates, specialists provide opinions and directors decide. The adviser may challenge a contribution or scenario but cannot set ownership, accept a milestone or speak for either party.

Current interests involving the counterparty, its investors, diagnostic competitors, research partners, laboratories, valuation firms or advisers create conflicts requiring disclosure before related papers are reviewed. Prior work on contributed IP must be named. The adviser receives no transaction success fee, warrant, carried interest or compensation linked to ownership outcome.

Why the board wants this voice

Both parties can reasonably value what they contribute while shifting risk in their preferred assumptions. Scientific, legal and finance experts address individual questions but no internal voice independently integrates contingent value. A seasoned JV valuation adviser can help directors see asymmetry without taking the negotiation mandate.

What you will own

• Challenge valuation of contributed IP, data, people, laboratory access, cash, customer relationships and retained rights separately.
• Model ownership and funding outcomes across development success, delay, technical failure, partner underperformance and early termination.
• Test milestone definitions for evidential clarity, controllability, timing, cost and unintended transfer of bargaining power.
• Examine shared-cost allocation, capacity use, follow-on capital, dilution, distribution and exit economics under each scenario.
• Probe whether territorial, field-of-use, licence and commercial rights align with the claimed contribution value.
• Shape board decision triggers for funding pause, scope change, partner default, buyout or dissolution.
• Frame an integrated value-and-risk ledger with assumptions, specialist dependencies, dissent and unresolved negotiation choices.

Candidate qualifications

• Advised or led valuation of a life-sciences joint venture combining IP, data, laboratories, scientists and staged capital.
• Modelled milestone-contingent ownership and funding where technical failure and commercial rights shifted value asymmetrically.
• Challenged contributed-asset values without substituting for scientific, tax, accounting or legal specialists.
• Connected capacity, development cost, licence boundaries and future commercial economics to governance and exit choices.
• Worked through contested partner negotiations while maintaining board-level independence and auditable assumptions.
• Advised directors without financial interests in counterparties, investors, laboratories, valuers or transaction completion.

Non-negotiables

• Can complete four board sessions and four partner, laboratory or commercial evidence reviews within ten months.
• Will disclose counterparty, diagnostics, investor, laboratory, research, valuation and transaction-adviser relationships.
• Brings contingent life-sciences JV valuation; conventional corporate valuation without scientific milestones is insufficient.
• Accepts no authority over negotiation, specialist opinions, ownership terms, capital approval or transaction execution.

1. 49 words maximum. Describe a JV contribution whose headline value changed materially under milestone failure or delay.
2. 49 words maximum. Which counterparty, investor, laboratory or valuer relationship could require your recusal?
3. 49 words maximum. What scenario best exposes asymmetry between contributed IP and future funding obligations?